The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2020
Filed:
Oct. 25, 2018
Applicant:
Oncorus, Inc., Cambridge, MA (US);
Inventor:
Luke Evnin, Cambridge, MA (US);
Assignee:
ONCORUS, INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 35/76 (2015.01); C07K 16/30 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 14/47 (2006.01); C12N 15/86 (2006.01); C12N 7/00 (2006.01); A61K 35/768 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 9/64 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 35/76 (2013.01); A61K 35/768 (2013.01); C07K 14/4703 (2013.01); C07K 14/522 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70503 (2013.01); C07K 14/70532 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/3092 (2013.01); C12N 7/00 (2013.01); C12N 9/6491 (2013.01); C12N 15/86 (2013.01); A61K 2039/507 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C12N 2710/16633 (2013.01); C12N 2710/16641 (2013.01); C12N 2740/16032 (2013.01); C12N 2740/16043 (2013.01); C12N 2760/20232 (2013.01); C12N 2760/20243 (2013.01); Y02A 50/466 (2018.01);
Abstract
Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.